Trasis

What we do: Trasis specializes in enabling the medical community to access new radiolabelled therapeutic and diagnostic substances more easily and quickly. The company designs, manufactures, sells, and supports high-performance synthesizers, dose preparation equipment, shielding, and accessories. Additionally, Trasis develops customized synthetic methods and instruments, provides GMP Active Pharmaceutical Ingredients (API), and assists customers with regulatory affairs. Their integrated solutions facilitate effective tracer production and accelerate the transition from drug development to marketing authorization. Their equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities, and pharmaceutical companies.

Where we are located: Trasis is headquartered at Rue Gilles Magnée, 90, 4430 Ans, Wallonia, Belgium.

Short history: Founded in 2004 by Gauthier Philippart and Jean-Luc Morelle, pioneers in radiosynthesizer technology, Trasis has grown into a global leader in radiopharmaceutical instrumentation. The founders combined their expertise to create innovative, GMP-compliant radiosynthesisers and dose dispensers. Over 20 years, the company has expanded its product range and workforce, reaching over 350 employees and €72 million in sales by 2024, with 98% of products exported worldwide.

Organization & culture: Trasis employs approximately 380 people as of 2024, organized into diverse teams focused on innovation, manufacturing, and customer support. The company values collaboration and diversity, with a culture rooted in teamwork and continuous progress. The co-founders’ partnership fosters a balanced and focused leadership style, emphasizing company goals over individual interests.

Recent developments: In 2024, Trasis experienced a record-breaking year, reinforcing its position as a global leader in nuclear medicine equipment. The company continues to innovate with upcoming product launches such as duoH and duoV, and maintains a strong commitment to supporting the radiopharmaceutical industry worldwide.